Peanut Peptide Immunoassay for Precise Allergy and Tolerance Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergy tests for peanut allergies are not sensitive or specific, do not distinguish different phenotypes, and lack prognostic information, posing challenges for precision medicine and oral immunotherapy safety.
Innovation Solution
A diagnostic method using two peanut peptides, WELQGDRRCQSQLER (SEQ ID NO:1) and DSYERDPYSPSQDPY (SEQ ID NO:2), coupled to a solid support, to detect allergy-associated immunoglobulins (AAIs) in a biological sample, with a labeling reagent to measure binding and determine peanut allergy or tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If spot membrane-based immunoassays with multiple peptides are used for epitope mapping, then diagnostic precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent segments the complex multi-peptide immunoassay into a simplified two-peptide system that specifically targets the two dominant IgE epitopes on Ara h 2. This segmentation maintains diagnostic precision by focusing on the most clinically relevant epitopes while reducing device complexity and cost by eliminating the need for numerous peptides and complex membrane-based systems.
Solution Approach 2:
The patent extracts and isolates the two most critical IgE-binding epitopes (residues 3-20 and 44-61) from the complete Ara h 2 protein sequence. By taking out only these essential epitopes for testing, the system achieves accurate diagnosis without requiring the full complexity of comprehensive epitope mapping, thereby reducing device complexity and reagent costs.
2Measurement precision
If comprehensive epitope mapping with many peptides is performed, then measurement precision is improved, but time consumption and labor intensity increase
Solution Approach 1:
The patent divides the extensive epitope mapping process into a focused assessment of only two critical epitopes. This segmentation enables rapid diagnosis by eliminating the time-consuming evaluation of numerous less-relevant peptides, while maintaining measurement precision through targeted detection of the dominant IgE-binding sites that correlate with clinical reactivity.
3Adaptability or versatility
If current IgE testing methods are used, then diagnostic capability is provided, but ability to predict clinical sensitivity and prognosis is insufficient
Solution Approach 1:
The patent applies local quality by focusing detection on specific regions (epitopes) of the Ara h 2 allergen that are most relevant to clinical outcomes. By measuring IgE binding to these localized epitopes rather than using crude extract-based tests, the system provides both diagnostic capability and prognostic information about clinical sensitivity and reaction severity, eliminating the information loss present in conventional methods.
4Reliability
If oral immunotherapy is administered to treat peanut allergy, then clinical benefit is achieved, but adverse reactions and therapy discontinuation rates increase
Solution Approach 1:
The patent implements feedback by using epitope-specific IgE measurement to monitor patient response to oral immunotherapy. By tracking changes in IgE binding to the two critical epitopes over time, clinicians can assess whether the patient is developing tolerance or remains at risk for adverse reactions, allowing for real-time adjustment of therapy to maximize clinical benefit while minimizing harmful effects and discontinuation rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides sensitive and specific diagnosis of peanut allergy and detection of clinical tolerance, improving precision medicine and oral immunotherapy safety by accurately assessing allergic reactions and treatment efficacy.
Implementation Method 1
contacting two peanut peptides coupled to a solid support with a biological sample obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the biological sample to the two peanut peptides
Implementation Method 2
contacting the AAI-peptide-solid support complexes with an AAI-specific labeling reagent to form labeling reagent-AAI-peptide-solid support complexes
Data Source
AI summary
The present disclosure provides peanut peptide compositions and kits, and methods for diagnosis of peanut allergy, methods for detecting the development of clinical tolerance to peanuts, and methods for desensitizing an infant to peanut allergens.